國家衛生研究院 NHRI:Item 3990099045/13259
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 855264      Online Users : 1047
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13259


    Title: Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes
    Other Titles: Long-term outcomes of adding α-glucosidase inhibitors in insulin-treated patients with type 2 diabetes
    Authors: Yen, FS;Wei, JC;Lin, MC;Hsu, CC;Hwu, CM
    Contributors: Institute of Population Health Sciences
    Abstract: BACKGROUND: In insulin-treated patients with type 2 diabetes mellitus (T2DM), glycemic control is usually suboptimal. METHODS: This study compared the risks of mortality and cardiovascular events in insulin-treated patients adding or not adding alpha-glucosidase inhibitors (AGIs). RESULTS: This cohort study included data from the Taiwan National Health Insurance Research Database. In total, 17,417 patients newly diagnosed as having T2DM and undergoing insulin therapy during 2000-2012 were enrolled. Overall incidence rates of all-cause mortality, hospitalized coronary artery disease (CAD), stroke, and heart failure were compared between 4165 AGI users and 4165 matched nonusers. The incidence rates of all-cause mortality were 17.10 and 19.61 per 1000 person-years in AGI nonusers and users, respectively. Compared with nonusers, AGI users had a higher mortality risk [adjusted hazard ratio (aHR) = 1.21, 95% confidence interval (CI) = 1.05-1.40; p = 0.01]. Regarding AGI use, aHRs (95% CI) for cardiovascular death, non-cardiovascular death, hospitalized CAD, stroke, and heart failure were 1.20 (0.83-1.74), 1.27 (1.07-1.50), 1.12 (0.95-1.31), 0.98 (0.85-1.14), and 1.03 (0.87-1.22) respectively. CONCLUSION: AGI use was associated with higher risks of all-cause mortality and non-cardiovascular death in insulin-treated patients with T2DM. Therefore, adding AGIs in insulin-treated patients may not be appropriate.
    Date: 2021-02-18
    Relation: BMC Endocrine Disorders. 2021 Feb 18;21:Article number 25.
    Link to: http://dx.doi.org/10.1186/s12902-021-00690-0
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1472-6823&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000621051600001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85100958849
    Appears in Collections:[Chih-Cheng Hsu] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB33602190.pdf954KbAdobe PDF205View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback